Lyell Immunopharma, Inc. (LYEL)
- Previous Close
2.2000 - Open
2.1900 - Bid 2.1500 x 400
- Ask 2.1800 x 300
- Day's Range
2.1100 - 2.2100 - 52 Week Range
1.3200 - 3.9700 - Volume
343,130 - Avg. Volume
909,350 - Market Cap (intraday)
553.213M - Beta (5Y Monthly) -0.56
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.33
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
lyell.comRecent News: LYEL
Performance Overview: LYEL
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LYEL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LYEL
Valuation Measures
Market Cap
553.21M
Enterprise Value
70.16M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.19k
Price/Book (mrq)
0.84
Enterprise Value/Revenue
539.67
Enterprise Value/EBITDA
-0.31
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-18.18%
Return on Equity (ttm)
-31.53%
Revenue (ttm)
130k
Net Income Avi to Common (ttm)
-234.63M
Diluted EPS (ttm)
-0.9300
Balance Sheet and Cash Flow
Total Cash (mrq)
546.22M
Total Debt/Equity (mrq)
9.65%
Levered Free Cash Flow (ttm)
-90.36M